ICU Medical (NASDAQ:ICUI), a medical device company specializing in infusion therapy and related products, released its second quarter results on August 7, 2025. The most important news from the report was a significant earnings per share (EPS) beat, with adjusted EPS of $2.10 (Non-GAAP) compared to analyst expectations of $1.50, a positive difference of 40.0% (Non-GAAP). Despite outperforming consensus numbers, GAAP revenue saw continued contraction and company guidance narrowed for FY2025, reflecting ongoing caution tied to regulatory challenges, tariffs, and shrinking sales in some segments.

Source: Analyst estimates for the quarter provided by FactSet.

The company develops, manufactures, and sells devices used to deliver medications and fluids to hospital patients. Its product range includes infusion pumps—electronic devices that control the rate at which fluids are delivered—IV sets and consumables, and hospital software systems for drug delivery safety. Infusion pumps are especially important in critical care settings, ensuring precise control of drug administration.

Continue reading

Source Fool.com